SequelSEC

INTEGRA LIFESCIENCES HOLDINGS CORP IART

Surgical & Medical Instruments & Apparatus · CIK 0000917520 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.65B
Fiscal year ended 2026-06-30
Operating income
$65.56M
Fiscal year ended 2026-06-30
Free cash flow
$25.80M
Fiscal year ended 2026-06-30

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported revenue of $1.65B and net income of -$7.24M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from INTEGRA LIFESCIENCES HOLDINGS CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

INTEGRA LIFESCIENCES HOLDINGS CORP income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$1.65B
Cost of revenue$783.08M
Gross profit$864.58M
Operating income$65.56M
Net income-$7.24M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$179.00K
Income tax expense$7.06M
Diluted EPS$-0.09
Selling, general & administrative$688.98M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

INTEGRA LIFESCIENCES HOLDINGS CORP balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$214.42M
Total assets$3.56B
Current assets$1.19B
Total liabilities$2.52B
Current liabilities$330.88M
Total equity incl. NCI$1.04B
Temporary (mezzanine) equityUnavailable
Inventory$492.00M
Accounts receivable$267.19M
Goodwill$611.14M
Long-term debt$707.19M
Accounts payableUnavailable

Cash flow

INTEGRA LIFESCIENCES HOLDINGS CORP cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$85.33M
Capital expenditures$59.52M
Investing cash flow-$108.63M
Financing cash flow$21.58M
Net change in cash-$3.50M
Stock-based compensation$22.43M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

INTEGRA LIFESCIENCES HOLDINGS CORP derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$25.80M
Gross margin52.5%
Operating margin4.0%
FCF margin1.6%
SBC / revenue1.4%
Current ratio3.60x
Revenue YoY growth1.6%
Net margin-0.4%
R&D / revenueUnavailable
CapEx / revenue3.6%
Long-term debt / equity0.68x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IART in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-29View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.